Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Garp1on Dec 01, 2009 9:02am

463 Views

Post# 16539238

RE: RE: RE: RE: TH holders...

Saurus,

You are correct.

The other possibility that could significantly shorten the approval period at this stage, would be get a priority review status from the FDA. This would only be possible if Thera would have requested it on or after they submitted there NDA (usually takes 45 days to get answer from FDA).

If granted by the FDA, this would be of material interest to the shareholder and therefore would have to be published.

Regards.

Bullboard Posts

Debt-free cannabis company set for next stage of growth